Tag Archives: #pharma

AdComms – Is FDA Getting Less Advice?

As more drugs are being approved, is FDA getting less advice than in the past? FDA maintains a vast network of outside advisors to provide input and counsel to the agency related to decisions on policy as well as product … Continue reading

Posted in Advisory Committee Prepapartion, FDA Image, FDA Policy | Tagged , , | Comments Off on AdComms – Is FDA Getting Less Advice?

OPDP Sends Untitled Letter

Upfront Author’s Note: This is the first posting in a while as I have been working to migrate the subscription service to a new provider. As such, some subscribers were lost in the process. Anyone who signed up for a … Continue reading

Posted in Warning Letters | Tagged , , | Comments Off on OPDP Sends Untitled Letter

Approvals in the Crazy Year of 2020

Each year in January, it is relevant to look back on the activities of FDA during the course of the previous year and look at how it was the same or different from prior years, and to look at trends … Continue reading

Posted in Advisory Committee Prepapartion, FDA Image, FDA Policy | Tagged , | Comments Off on Approvals in the Crazy Year of 2020